Immorna Biotherapeutics, Inc.
7
0
2
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 7 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
Role: lead
A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV
Role: lead
One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors
Role: lead
Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors
Role: lead
A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine
Role: lead
A Phase 1 Study to Assess the Safety and Immunogenicity of JCXH-221, an MRNA-based Broadly Protective COVID-19 Vaccine
Role: lead
Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors
Role: lead
All 7 trials loaded